Moderna Zika Vaccine

All 11 severe cases of covid 19 in moderna s trial happened in participants who received a placebo shot.

Moderna zika vaccine. As mentioned above the moderna contract is an agreement concerning a potential zika vaccine from 2016. The team behind the moderna vaccine is led by tal zaks. Moderna s vaccine is based on a new kind of technology. It has 23 mrna drugs and vaccines in its portfolio such as vaccines for the zika virus bird flu and herpes.

Ahead of its vaccines day event today moderna nasdaq mrna reports positive results from a phase 1 study of its zika vaccine candidate mrna 1893. This agreement was of interest to kei as through our research into moderna s covid 19 vaccine efforts it appears that the funding from this zika research agreement helped support the development of the moderna mrna platform technology underlying its covid 19 vaccine efforts. So far moderna has conducted early trials with success on nine vaccine candidates including respiratory syncytial virus rsv human metapneumovirus hmpv and parainfluenza virus piv3 influenza h7n9 cytomegalovirus cmv zika epstein barr chikungunya and of course is running the trial on the novel coronavirus that causes covid 19. Zikv is a member of the flavivirus genus of the flaviviridae family of enveloped rna viruses.

Moderna noted in its release that it has recorded 11 severe cases of covid 19 among trial participants. Zikv has an 11 kb positive sense rna genome. But since the pandemic began. So the zika vaccine the cmv vaccine if this vaccine shows high efficacy they are going to have high efficacy.

Our zika program is part of moderna s broader commitment to improving global public health through developing mrna vaccines to prevent the spread of infectious diseases mrna 1893 contains an mrna sequence encoding for the structural proteins of zika virus and is designed to cause cells to secrete virus like particles mimicking the response of the cell after natural infection. The biotech company moderna unveiled promising early data from a phase 1 trial of its experimental zika vaccine on tuesday morning which could be a good sign for the company s covid 19. Preliminary results for the 10 µg and 30 µg. It s just science 6.

The research was conducted by scientists from the national institute of allergy and infectious diseases niaid part of the national institutes of health nih and washington university school of medicine and utmb.